Abstract
ANS-6637, an orally bioavailable selective and reversible aldehyde dehydrogenase-2 (ALDH2) inhibitor, is under development for drug and alcohol use disorders. During the elimination of alcohol, ALDH2 metabolizes acetaldehyde to acetate; inhibiting this enzyme can lead to aversive reactions due to the accumulation of acetaldehyde. Thus, understanding the safety and tolerability of ANS-6637 in combination with alcohol is essential. Forty eight healthy males participated in a randomized, double-blind, placebo-controlled, single-ascending dose cohort study of oral ANS-6637. Eligible participants were randomized to ANS-6637 (n = 36) or placebo (n = 12) in a 3:1 fashion in each of 6 dose cohorts (8 per cohort; ANS-6637 dose levels were 25, 50, 100, 200, 400, and 600 mg). Two hours after receiving study drug, participants drank up to 5 standard drinks, 1 every 30 minutes. Safety assessments, pharmacodynamic measures, and pharmacokinetic blood samples were obtained. Flushing was the most common adverse event (AE) associated with ANS-6637 (24 of 36 participants) compared with placebo (3 of 12). Statistically significant, but modest, increases in heart rate (HR) occurred (+10.5 bpm after 2 drinks; +16.9 to + 20.5 bpm after 3rd through 5t...Continue Reading
References
Apr 1, 1979·Clinical Pharmacology and Therapeutics·J F BrienB J Rogers
Jan 1, 1992·Pharmacology & Toxicology·J JohnsenJ Mørland
Mar 1, 1991·Pharmacology & Toxicology·B JohanssonP Rønsted
Mar 1, 1991·Pharmacology & Toxicology·J K ChristensenB Johansson
Dec 1, 1989·Alcoholism, Clinical and Experimental Research·M T Ryzlak, R Pietruszko
Nov 1, 1987·Clinical Pharmacokinetics·N H Holford
Jul 1, 1995·American Journal of Public Health·H WechslerE B Rimm
Dec 6, 1996·The Journal of Biological Chemistry·X WangH Weiner
Jan 6, 2001·Pharmaceutical Research·B P SmithS T Forgue
Dec 18, 2001·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rui-Sheng WangTakeshi Honma
Mar 4, 2008·British Journal of Pharmacology·M W Feltenstein, R E See
Jul 11, 2008·Journal of Medicinal Chemistry·Edward D LoweWing Ming Keung
May 16, 2009·Drug and Alcohol Dependence·Lawrence P Carter, Roland R Griffiths
Aug 14, 2009·Alcoholism, Clinical and Experimental Research·Maria P ArolfoIvan Diamond
Aug 24, 2010·Nature Medicine·Lina YaoIvan Diamond
Jun 24, 2011·Drug and Alcohol Dependence·John D RoacheAhmed Elkashef
Mar 30, 2012·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Kyung-Yeol BaeJin-Sang Yoon
May 1, 2012·Pharmacological Reviews·Vindhya KoppakaVasilis Vasiliou
Oct 30, 2012·Clinics in Liver Disease·Arthur I Cederbaum
Dec 29, 2012·Psychopharmacology·Meghan E MoreanStephanie S O'Malley
Aug 6, 2013·Alcoholism, Clinical and Experimental Research·Ching-Long LaiShih-Jiun Yin
Jun 4, 2015·JAMA Psychiatry·Bridget F GrantDeborah S Hasin
Nov 19, 2015·JAMA Psychiatry·Bridget F GrantDeborah S Hasin
Jan 28, 2016·The New England Journal of Medicine·Nora D VolkowA Thomas McLellan
Mar 19, 2016·Pharmacopsychiatry·J MutschlerS Rösner
Oct 28, 2016·The Journal of Clinical Psychiatry·S Patricia ChouBridget F Grant